Our group aims to develop new T-cell based concepts for cancer immunotherapy that overcome the major challenge of self-tolerance in cancer. To this end, one of our main strategies involves studies of how the immune system from healthy donors can target patient cancer cells. We have a strong focus on the development of new technologies that allow high-throughput identification of therapeutic targets that can evoke immune responses, as lack of immunogenic targets represents a major limitation in therapeutic efficacy. The group furthermore has a strong translational focus and performs penetrating mechanistic analyses in clinical trials together with our clinical partners. The group is a member of K.G. Jebsen Center for Cancer Immunotherapy (Center Director: Olweus).
A woman in her forties with influenza symptoms and swollen arm
Tidsskr Nor Laegeforen, 139 (1)
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
Cancer Immunol Res, 6 (4), 467-480
The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy
Front Immunol, 8, 1718